Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J.

Science. 2000 Sep 15;289(5486):1938-42.

2.

c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571).

Nagar B.

J Nutr. 2007 Jun;137(6 Suppl 1):1518S-1523S; discussion 1548S.

3.

Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).

Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J.

Cancer Res. 2002 Aug 1;62(15):4236-43.

4.

STI-571: an anticancer protein-tyrosine kinase inhibitor.

Roskoski R Jr.

Biochem Biophys Res Commun. 2003 Oct 3;309(4):709-17. Review.

PMID:
13679030
5.
6.

Structural basis for the autoinhibition of c-Abl tyrosine kinase.

Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J.

Cell. 2003 Mar 21;112(6):859-71.

7.

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.

Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10700-5. Epub 2002 Jul 29.

8.

Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase.

Dorey K, Engen JR, Kretzschmar J, Wilm M, Neubauer G, Schindler T, Superti-Furga G.

Oncogene. 2001 Dec 6;20(56):8075-84.

9.

C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.

Santucci MA, Corradi V, Mancini M, Manetti F, Radi M, Schenone S, Botta M.

ChemMedChem. 2009 Jan;4(1):118-26. doi: 10.1002/cmdc.200800320.

PMID:
19039816
10.

A myristoyl/phosphotyrosine switch regulates c-Abl.

Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuriyan J, Superti-Furga G.

Cell. 2003 Mar 21;112(6):845-57.

11.

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB.

J Pharmacol Exp Ther. 2000 Oct;295(1):139-45.

12.

Cancer research. Why some leukemia cells resist STI-571.

Marx J.

Science. 2001 Jun 22;292(5525):2231-3. No abstract available.

PMID:
11423629
13.
14.

Molecular biology. Cancer fighter's modus operandi revealed.

Marx J.

Science. 2000 Sep 15;289(5486):1857-9.

PMID:
11012350
15.
17.

Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.

Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, Snell GP, Zou H, Sang BC, Wilson KP.

J Biol Chem. 2004 Jul 23;279(30):31655-63. Epub 2004 Apr 29.

18.

Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.

Koch A, Scherr M, Breyer B, Mancini A, Kardinal C, Battmer K, Eder M, Tamura T.

Oncogene. 2008 Aug 7;27(34):4678-89. doi: 10.1038/onc.2008.107. Epub 2008 Apr 21.

PMID:
18427551
19.

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL.

Science. 2001 Aug 3;293(5531):876-80. Epub 2001 Jun 21.

20.

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.

Blood. 2004 Oct 15;104(8):2532-9. Epub 2004 Jul 15.

Supplemental Content

Support Center